ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 153 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2017. The put-call ratio across all filers is 2.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $2,893,000 | -21.5% | 40,000 | -28.6% | 0.99% | -30.5% |
| Q4 2017 | $3,687,000 | +437.5% | 56,000 | +308.8% | 1.42% | +623.4% |
| Q3 2017 | $686,000 | -68.1% | 13,700 | -47.9% | 0.20% | -79.6% |
| Q2 2015 | $2,151,000 | -15.5% | 26,300 | -4.4% | 0.97% | -43.0% |
| Q1 2015 | $2,546,000 | – | 27,500 | – | 1.70% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |